FRA:LUP (China)
Â
Ordinary Shares - Class H
€
0.29
+0.0060 (+2.11%)
Mar 28
Warning! GuruFocus detected
4 Severe warning signs
with LUP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Luye Pharma Group Ltd
NAICS : 325412
SIC : 2834
ISIN : BMG570071099
Share Class Description:
FRA:LUP: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
02186.Hong KongLUP.GermanyLYPHF.USA IPO Date
2014-08-14Description
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | 3.96 | |||||
| Interest Coverage | 2.25 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.97 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.3 | |||||
| 3-Year EBITDA Growth Rate | -4.4 | |||||
| 3-Year EPS without NRI Growth Rate | -25.4 | |||||
| 3-Year Book Growth Rate | 6.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 40.29 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.52 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.63 | |||||
| 9-Day RSI | 65.95 | |||||
| 14-Day RSI | 61.31 | |||||
| 3-1 Month Momentum % | 11.36 | |||||
| 6-1 Month Momentum % | -20.97 | |||||
| 12-1 Month Momentum % | -6.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.66 | |||||
| Days Inventory | 151.22 | |||||
| Days Sales Outstanding | 119.19 | |||||
| Days Payable | 137.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | 8.41 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.74 | |||||
| Operating Margin % | 23.1 | |||||
| Net Margin % | 12.2 | |||||
| FCF Margin % | 8.13 | |||||
| ROE % | 6.25 | |||||
| ROA % | 2.92 | |||||
| ROIC % | 5.55 | |||||
| 3-Year ROIIC % | -6.2 | |||||
| ROC (Joel Greenblatt) % | 25.86 | |||||
| ROCE % | 9.93 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.35 | |||||
| Forward PE Ratio | 8.3 | |||||
| PE Ratio without NRI | 12.72 | |||||
| Shiller PE Ratio | 8.56 | |||||
| Price-to-Owner-Earnings | 48.63 | |||||
| PS Ratio | 1.39 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 1.61 | |||||
| Price-to-Free-Cash-Flow | 16.88 | |||||
| Price-to-Operating-Cash-Flow | 16.88 | |||||
| EV-to-EBIT | 7.48 | |||||
| EV-to-Forward-EBIT | 10.07 | |||||
| EV-to-EBITDA | 5.21 | |||||
| EV-to-Forward-EBITDA | 7.45 | |||||
| EV-to-Revenue | 1.96 | |||||
| EV-to-Forward-Revenue | 1.73 | |||||
| EV-to-FCF | 23.8 | |||||
| Price-to-GF-Value | 0.73 | |||||
| Price-to-Projected-FCF | 1.81 | |||||
| Price-to-Median-PS-Value | 0.45 | |||||
| Price-to-Graham-Number | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 13.37 | |||||
| FCF Yield % | 5.98 | |||||
| Forward Rate of Return (Yacktman) % | -16.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Luye Pharma Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 809.689 | ||
| EPS (TTM) (€) | 0.026 | ||
| Beta | 0.5 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.05 | ||
| Volatility % | 28.88 | ||
| 14-Day RSI | 61.31 | ||
| 14-Day ATR (€) | 0.005316 | ||
| 20-Day SMA (€) | 0.2758 | ||
| 12-1 Month Momentum % | -6.96 | ||
| 52-Week Range (€) | 0.25 - 0.402 | ||
| Shares Outstanding (Mil) | 3,761.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Luye Pharma Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Luye Pharma Group Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Luye Pharma Group Ltd Frequently Asked Questions
What is Luye Pharma Group Ltd(FRA:LUP)'s stock price today?
The current price of FRA:LUP is €0.29. The 52 week high of FRA:LUP is €0.40 and 52 week low is €0.25.
When is next earnings date of Luye Pharma Group Ltd(FRA:LUP)?
The next earnings date of Luye Pharma Group Ltd(FRA:LUP) is .
Does Luye Pharma Group Ltd(FRA:LUP) pay dividends? If so, how much?
Luye Pharma Group Ltd(FRA:LUP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers